Loading
The second planned analysis of OlympiA, at 3.5 years, in which a year of olaparib tablets after standard treatment cut deaths by 32 percent in women with an inherited BRCA fault, the first time a PARP inhibitor had lengthened life in early breast cancer.
Geyer, Garber, Gelber, Yothers and colleagues report the pre-specified second interim analysis of overall survival in OlympiA, which randomised 1,836 patients with germline BRCA1 or BRCA2 pathogenic variants and high-risk HER2-negative early breast cancer to a year of olaparib or placebo after neoadjuvant or adjuvant chemotherapy, surgery and radiotherapy. With a median follow-up of 3.5 years overall survival improved (hazard ratio 0.68, 98.5 percent confidence interval 0.47 to 0.97, p=0.009); four-year overall survival was 89.8 versus 86.4 percent (difference 3.4 percentage points), four-year invasive disease-free survival 82.7 versus 75.4 percent (7.3 points) and distant disease-free survival 86.5 versus 79.1 percent (7.4 points), with benefit across major subgroups and no new safety signals, including no new acute myeloid leukaemia or myelodysplastic syndrome.
The survival result that moved adjuvant olaparib from a disease-free survival approval to an undisputed standard, and the reason germline testing at diagnosis of triple-negative breast cancer is now a treatment decision rather than a family history exercise.
Shares Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial, OlympiA, Olaparib, BRCA1 / BRCA2 (HRD) and the tag tnbc-evidence.
Shares OlympiA, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag tnbc-evidence.
Shares OlympiA, Annals of Oncology, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Charles E. Geyer Jr., Annals of Oncology, PARP inhibitors, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Annals of Oncology, Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Annals of Oncology, Overall survival (OS), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, AstraZeneca and the tag tnbc-evidence.